Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Asthma
Interventions
HXe MRI guided treatment sequence for BT, Standard treatment sequence for BT (control)
Drug · Other
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Obesity
Interventions
Xenon
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Functional Applications of Hyperpolarized 129Xe MRI

NCT01697332
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized 129Xe gas
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 2 Interventional Accepts healthy volunteers

129Xe MRI Cardiopulmonary

NCT06038630
Conditions
Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Interventions
Hyperpolarized Xe129, Oxygen Administration
Drug · Other
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

NCT04071769
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Thoracic Insufficiency Syndrome
Interventions
Xenon-129
Device
Lead sponsor
Patrick Cahill, MD
Other
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133XE scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Hyperpolarized xenon MRI
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Dual MRI for Cardiopulmonary COVID-19 Long Haulers

NCT04828135
Conditions
Covid19
Interventions
Hyperpolarized 129Xenon gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
Interventions
Hyperpolarized 129 Xenon
Combination Product
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
Drug · Device
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Cystic Fibrosis
Interventions
Xenon MRI
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

NCT04467957
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator, Hyperpolarized Xenon 129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Covid19
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Imaging Techniques
Interventions
Xenon MRI, Pulmonary Function Testing, Quality of Life Questionnaire, Medical Research Council Dyspnea score, St. George's Respiratory Questionnaire, Blood Biomarkers
Drug · Diagnostic Test · Other
Lead sponsor
Sean Fain
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized Xenon-129 MR Imaging of the Lung

NCT04662658
Conditions
E-Cig Use
Interventions
Hyperpolarized Xenon -129 MRI
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Healthy
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
25 Years to 35 Years
Enrollment
260 participants
Timeline
2023 – 2027
U.S. locations
6
States / cities
Chicago, Illinois • Iowa City, Iowa • Kansas City, Kansas + 2 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Cystic Fibrosis
Interventions
hyperpolarized Xenon gas
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
20 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133 Xe scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Cincinnati, Ohio • Charlottesville, Virginia